Ocular Therapeutix Inc (OCUL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ocular Therapeutix Inc   (NASDAQ: OCUL)


Ocular Therapeutix Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ocular Therapeutix Inc's ROI in the second quarter of 2026?
Ocular Therapeutix Inc recorded a cumulative net loss of $-301 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -49.53%.

Within the Healthcare sector 460 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2197 to 3747.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 51.15 % 33.41 % 6.17 % -3.21 % 27.51 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 622 688 760 364 411
Return On Investment (TTM) -49.53 % -52.26 % -55.89 % -64.82 % -53.83 %
OCUL's Overall Ranking # 3747 # 2197 # 2630 # 3518 # 3319
Seq. Investment Change TTM 9.49 % 16.81 % 23.55 % -4.35 % -3.36 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -301 -290 -266 -250 -217

OCUL Company Profile >> Back to OCUL Roi Comparisons >> See Annual OCUL Return On Investment



Return On Investment OCUL's Ranking
Within: No.
Industry # 190
Sector # 461
Overall # 3747

Return On Investment Statistics
High Average Low
-3.29 %
-66.76 %
-137.34 %
  (Jun 30 2020)



  News about Ocular Therapeutix Inc Return on Investment ROI

Ocular Therapeutix Accelerates Wet AMD Trials Amid Strategic Expansion and Legal Expertise Enhancements

October 15, 2024

Ocular Therapeutix Accelerates Wet AMD Trials Amid Strategic Expansion and Legal Expertise EnhancementsIn the dynamic landscape of biopharmaceutical innovation, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has taken decisive steps towards solidifying its status as a pioneering leader in developing transformative therapies for retinal diseases and ocular conditions. Based in Bedford, Massachusetts, the company is increasingly making

Ocular Therapeutix Bolsters Clinical Team with Renowned Retinal Experts, Addressing Past Financial Challenges

April 16, 2024



Ocular Therapeutix Inc, a leading biopharmaceutical company specializing in innovative eye therapies, recently announced significant additions to its clinical team. This strategic move aims to strengthen the company s medical expertise and propel its research and development efforts forward. Nadia K. Waheed, MD, MPH, has been appointed as the Chief Medical Officer, while Peter K. Kaiser, MD, will assume the role of Chief Development Officer. Additionally, Andrea Gibson, PhD, has been named Vice President of Medical Collaborations, and Namrata Saroj, OD, joins as the Development Strategy Consultant. This article delves into the implications of these appointments and analyzes their potential impact on Ocular Therapeutix s future prospects, considering the company s recent financial challenges.

Ocular Therapeutix Inc has made a strategic move to fortify its clinical team with the inclusion of renowned retinal experts. These appointments represent a strategic effort by the company to leverage their expertise in advancing its product pipeline and addressing previously reported financial challenges. The new additions are expected to augment the company s clinical capabilities and pave the way for the development of breakthrough eye therapies.

Ocular Therapeutix Grants Inducement Equity Awards to New SVP of Global Head of Biometrics Amidst Financial Challenges

April 9, 2024


In a recent announcement, Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on developing and commercializing innovative therapies for eye-related diseases, revealed that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu. These awards were approved by Ocular s Compensation Committee and were offered to Dr. Zhu as an incentive for joining the company.
Ocular Therapeutix is committed to improving people s vision and quality of life by creating treatments for conditions such as wet age-related macular degeneration (wet AMD) and diabetic retinopathy. The company aims to bring innovative therapies to market that address the unmet medical needs of patients with eye-related diseases.





Financial Statements
Ocular Therapeutix Inc's II. Quarter Investments $ 622 Millions OCUL's Balance sheet
Ocular Therapeutix Inc's II. Quarter Income $ -79 Millions Quarterly OCUL's Income Statement
OCUL's Income by Division See OCUL's Income by Division


OCUL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 740 397 196 96 160
Y / Y Investment Growth 86.4 % 102.52 % 104.69 % -39.97 % -25.98 %
Net Income in Millions -266 -194 -81 -71 -7
Y / Y Net Income Growth - - - - -
Annual Return On Investment -35.92 % -48.71 % -41.16 % -74.13 % -4.11 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
OCUL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for OCUL's Competitors
Subscribers only: Roi for Ocular Therapeutix Inc's Suppliers
Subscribers only: Return On Investment for OCUL's Customers

Other Ratios
OCUL's Roa OCUL's Inventory Turnover Ratio OCUL's Growth Rates OCUL's Dividend Statistics
OCUL's Profitability Ratios OCUL's Asset Turnover Ratio OCUL's Dividend Growth
OCUL's Roe OCUL's Valuation Ratios OCUL's Financial Strength Ratios OCUL's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-13T23:37:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.